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Sleep−disordered breathing in heart failure 
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INTRODUCTION
Heart failure (HF) is a major and increasing public health pro-
blem. Despite advances in medicine, the disease remains
common. Among Framingham Heart Study subjects, the risk
of developing congestive HF was estimated as 20% [1]. The
chronic and progressive character of HF is related to signifi-
cantly compromised life quality, increased need for medical
care and poor prognosis. Since these issues remain unsolved,
great efforts have been made to identify and manage modi-
fiable factors that might be responsible for the thus far unsa-
tisfactory results of HF treatment. One of these factors is pro-
bably sleep-disordered breathing.
The major types of sleep-disordered breathing (SDB) in
HF are shown in Table 1. They include obstructive sleep ap-
noea (OSA) and central sleep apnoea (CSA) which may ma-
nifest in periodic (Cheyne-Stokes) respiratory pattern.
Apnoea is defined as cessation of airflow for ten or more
seconds. Hypopnoea is usually understood as reduced air-
flow (> 50%) or impairment of respiratory movements of chest
and abdomen with oxygen blood saturation decreased by at
least 4% and/or arousal [2].
In order to assess the severity of SDB, an apnoea-hypop-
noea index (AHI) is calculated. Its value represents the num-
ber of apnoea and hypopnoea episodes during an hour of
sleep. According to criteria proposed for OSA, the diagnosis
is confirmed when AHI is greater than 15, or greater than five
in a patient with symptoms [3]. The gold standard for apnoea
detection and assessment is polysomnography. However,
there is evidence that Holter ECG monitoring may be a use-
ful method of sleep apnoea diagnosis [4].
Obstructive sleep apnoea (Table 1) is characterised by a pe-
riodic collapse of the airways that prevents inhalation despite
respiratory effort. During sleep, the muscles that maintain pa-
tent airways are relaxed and an obstruction may occur, espe-
cially in obese individuals with narrowed airways. Despite re-
spiratory movements of chest and abdomen, the airflow ce-
ases. After nervous system activation and arousal, the respira-
tory effort is increased and the airflow is restored. This type of
SDB contributes to a number of cardiovascular (CV) problems.
Central sleep apnoea (Table 1) probably arises as a con-
sequence of HF and is characterised by a periodic lack of
central respiratory drive. When a patient lies supine, pulmo-
nary congestion stimulates vagal irritant receptors in the lungs,
causing hyperventilation. Increased ventilation results in re-
duction in PaCO2 even below the threshold level required to
stimulate breathing. Efferent activity to the respiratory pump
muscles is reduced. With lack of central drive, the respiratory
effort ceases. As a consequence, PaCO2 rises and ventilation
Table 1. Major types of sleep-disordered breathing (SDB)
Type of SDB Characteristics
Obstructive sleep apnoea Collapse of airways
Respiratory effort against obstruction during apnoea
Central sleep apnoea Likely consequence of heart failure
Periodic lack of central respiratory drive
No respiratory effort during apnoea
Cheyne-Stokes respiratory pattern
Mixed sleep apnoea Both central and obstructive factors contribute to apnoea episode
Possible gradual shift between predominant mechanisms of apnoea during the night
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is restored. Arousals are not required for airflow initiation;
they frequently occur later and stimulate hyperventilation. The
length of ventilatory phase is inversely proportional to car-
diac output, which reflects delay in transmission of blood gas
tensions from lungs to chemoreceptors. In HF, prolonged cir-
culation results in Cheyne-Stokes respiratory pattern. This type
of SDB may be developed on the HF background and then
additionally complicates a patient’s status.
Mixed sleep apnoea (Table 1) is quite a common situ-
ation. In this type of apnoea, during the apnoeic event, both
central and obstructive factors contribute to breathing distur-
bance. The episode usually begins with a reduced central re-
spiratory drive, followed by obstruction. A gradual shift from
predominantly obstructive apnoeas in the early hours of
sleep to mainly central apnoeas at the end of the night has
been described in such cases [5].
In some patients with OSA, after introducing treatment
with CPAP/BiPAP (i.e. types of mechanical ventilation: conti-
nuous positive airway pressure/bi-level positive airway pres-
sure), there is the persisting or newly arising component of
CSA. Before treatment, SDB consists of entirely or predomi-
nantly obstructive apnoeas which then convert to entirely or
predominantly central apnoeas. In such cases, complex sleep
apnoea (CompSA) may be diagnosed.
Clinical manifestations of obstructive sleep apnoea inc-
lude not only disturbed sleep but also all the consequences
for everyday life quality; thus the symptoms can be divided
into nocturnal and daytime (Table 2). In patients with SDB,
arrhythmia such as atrial fibrillation (AF) or ventricular extra-
systoles is more common.
As shown in Table 2, some of the symptoms of SDB are
similar to those of HF or the effects of medicines, which may
be misleading for the physician. Simple tools designed to as-
sess symptoms of apnoea may be helpful, for example the
Epworth Sleepiness Scale or the Berlin Questionnaire. Me-
thods using Holter ECG monitoring to calculate risk of apno-
ea may be used in further examination. The awareness of
apnoea prevalence and risk factors or indicators of sleep-
-disordered breathing allows early diagnosis.
In a large study on a representative sample of the Bang-
kok population [6], based on 4,680 interviews, 4% of sub-
jects (5.3% of men and 3.5% of women) complained of habi-
tual snoring (> 3 nights/week) and excessive daytime sleepi-
ness (> 3 days/week) over the course of at least three mon-
ths. Individuals reporting SDB were older, had greater body
mass index (BMI), neck size, and waist circumference. They
complained of shorter nocturnal sleep, awakenings, unrefre-
shing sleep, choking, night sweats, nycturia, and bruxism. Re-
garding a Western population, there is evidence from the Sleep
Heart Health study [7] conducted on 5,615 community-dwel-
ling men and women aged between 40 and 98. The authors
clearly defined SDB according to AHI. In the total sample,
53% of subjects had AHI < 5, 29% had AHI from 5 to 14,
and 18% had AHI ≥ 15. The authors of the Wisconsin Sleep
Cohort study [8], which involved 602 employed men and
women aged 30 to 60, estimated the prevalence of SDB
(AHI ≥ 5) to be 9% for women and 24% for men.
The prevalence of OSA syndrome in the general popula-
tion aged 30–60 is assessed as 2–4%. Apnoea is 2–3 times
more common in men than in women. In middle-aged indi-
viduals, the prevalence is 5% for females and 15% for males.
In a population aged 65–95, AHI ≥ 10 is found in 56% of
women and 70% of men [9]. In adults with diabetes, the pre-
valence of AHI ≥ 10 is 48% and AHI ≥ 20 is 29%. The OSA
is diagnosed in 30–40% of obese individuals with BMI > 40.
The data concerning HF patients is even more bothe-
ring, since many reports indicate a very high prevalence of
SDB in this group. According to the literature, most of this
population experience different forms of the problem. For
example, Javaheri et al. [10] found CSA in 40% and OSA in
11% of HF patients. In another study, Sin et al. [11] examined
450 patients with ejection fraction (EF) of 27.3 ± 15.6%. Using
an AHI cut-off of 10, 15 and 20 per hour of sleep, the overall
occurrences of SBD were 72%, 61% and 53%, respectively;
of CSA they were 33%, 29% and 25%, respectively; and of
OSA they were 38%, 32% and 27%, respectively. Oldenburg
et al. [12] screened 700 patients with congestive HF (NYHA ≥
≥ II class, EF £ 40%) using cardiorespiratory polygraphy. The
SDB was present in as much as 76% of patients (40% CSA,
36% OSA). As regards the severity of SDB in these patients,
a mild (AHI = 6–14/h) form of CSA was present in 8% and
mild OSA in 17%. More than 50% of the subjects had mode-
rate to severe SDB with AHI of ≥ 15/h (specifically CSA 32%,
OSA 19%). The authors suggest that CSA may be a marker of
HF severity.
It should be noted that Cheyne-Stokes respiratory pat-
tern may also be present during the daytime in patients with
severe congestive HF. Brack et al. [13] monitored 60 patients
during 24 h of routine activities with a portable respiratory
inductive plethysmograph. During the night, 62% of patients






Fragmented sleep Lack of concentration
Arousals Falling asleep during work or
Nycturia when driving a car, accidents
Sweating Mood disorders
Gastro-oesophageal reflux Sexual dysfunction
(in obstructive sleep apnoea)
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had ≥ 15 periodic breathing cycles per hour, and during the
day the prevalence was 16%! The authors determined that
Cheyne-Stokes respiration during ≥ 10% of the daytime was
an independent predictor of mortality.
On the basis of many studies, several risk factors particu-
larly indicative of the probability of significant SDB have been
identified. These features, especially several of them coexi-
sting in one patient, should encourage further examination.
Obese hypertensive men aged ≥ 60 years reporting snoring
probably suffer from SDB. Sometimes the family may provi-
de information about witnessed apnoea. The patient would
complain of fatigue after awakening and excessive daytime
sleepiness, morning headaches, and insomnia. The SDB may
be suspected [11] in patients with episodes of angina and
during sleep, paroxysmal nocturnal dyspnoea, low PaCO2,
AF or ventricular arrhythmia, worsening systolic or diastolic
dysfunction of left ventricle (LV), implantable cardioverter-
-defibrillator, patients complaining of restless sleep and candi-
dates for cardiac transplantation.
PATHOPHYSIOLOGY
In patients with SDB, physiological variability patterns of sym-
pathetic nervous system activity dependent on sleep phases
is disturbed by recurring episodes of apnoea. Apnoeas cau-
se hypoxia and hypercapnia and these stimulate chemore-
ceptors to activate the sympathetic nervous system, inclu-
ding nerves in the walls of blood vessels. In patients with
congestive HF, blood pressure fluctuations during Cheyne-
-Stokes respiration related to oscillations in ventilation have
been observed [14]. In OSA at the end of each apnoea epi-
sode, sympathetic activation reaches a maximum level. Blo-
od pressure, even in normotensive individuals, may rise as
high as 250/110 mm Hg [15]. Recurrent hypoxemic stress
seems to increase endothelin secretion and induces vaso-
constriction. Catecholamines levels are elevated. Impairment
of autonomic regulation extends to daytime, which is re-
flected by greater variations in blood pressure levels but di-
minished heart rate variability. Similarly, it has been demon-
strated that in HF, CSA is associated with elevated sympa-
thoneural activity, measured as nocturnal urinary and dayti-
me plasma norepinephrine concentrations. After using nasal
CPAP, norepinephrine concentrations were significantly re-
duced [16].
INFLUENCE OF SDB ON CLINICAL COURSE
AND PROGNOSIS IN HEART FAILURE
As mentioned before, SDB is related to decreased quality of
life [17]. Besides subjective complaints of the patients, there
are many consequences of long-term negative impact of ap-
noea on the CV system. According to a prospective study on
6,441 men and women participating in the Sleep Heart He-
alth study [18], SDB was associated with all-cause mortality.
This relationship was particularly noted in men aged 40–70,
and the authors suggested a connection to mechanisms in-
volving intermittent hypoxemia and coronary artery disease
(CAD).
OSA
The OSA is nowadays considered to be an important back-
ground of some cases of arterial hypertension previously re-
cognised as idiopathic. The OSA is a common finding in hy-
pertensive individuals, especially those who are obese, diffi-
cult to treat and who have a non-dipper profile (lack of nor-
mal fall of blood pressure during the night). The ESH/ESC
guidelines from 2007 [19] advise exclusion of OSA with se-
condary hypertension in such cases. Rising blood pressure is
a direct mechanism by which OSA might induce LV systolic
dysfunction. Hypertension is the risk factor for ventricular hy-
pertrophy and failure, and OSA has been shown to be rela-
ted to hypertrophy of the myocardium, increased LV mass
and impaired function. This influence increases with higher
AHI and could be reversible with effective CPAP therapy.
The prevalence of insulin resistance and metabolic syn-
drome rises with the severity of OSA. Increased levels of in-
flammation markers were also observed. The presence of OSA
is related to higher prothrombotic activity, with increased
markers of thrombotic risk. It has been shown that excretion
of urine albumins may be related to the presence and severi-
ty of apnoea [20]. This might be a sign of underlying endo-
thelium dysfunction in patients with OSA. Patients with OSA
(with or without CV disease) have been shown to report more
premature deaths of CV causes in their family history. The
OSA causes repetitive forced inspiration, with substantial ne-
gative pressures in the chest cavity, to levels approaching
65 mm Hg. Pressure changes cause increased transmural gra-
dients across the atria, ventricles and aorta, and may disrupt
ventricular function.
Arrhythmias are frequent in OSA (nocturnal arrhythmias
in up to 50% patients) and the prevalence of rhythm distur-
bances rises with AHI and the severity of the associated hy-
poxemia. Different forms of arrhythmia have been described:
ventricular beats with nonsustained ventricular tachycardia,
bradyarrhythmia-like sinus arrest or second-degree atrioven-
tricular conduction block and AF [21]. Untreated OSA gre-
atly increases the risk for recurrence of AF after successful
cardioversion. A recent study in a large cohort of older men
showed that increasing severity of SDB was associated with
a progressive increase in the likelihood of AF and complex
ventricular ectopy. As regards central or obstructive types of
SDB, complex ventricular arrhythmia was associated most
strongly with OSA and hypoxia, whereas AF was associated
with CSA. These findings suggest that different forms of sleep-
-related stresses may contribute to atrial and ventricular
arrhythmogenesis in older men [22].
In individuals with no history of CAD who underwent
computed tomography, coronary artery calcification score was
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shown to be related to OSA. Patients with CAD significantly
more often have coexisting OSA than the controls. The rela-
tionship between ischaemic heart disease and OSA is inde-
pendent of gender, age, BMI, arterial hypertension and dia-
betes [23, 24].
Shahar et al. [25] studied a subgroup consisting of 6,424 in-
dividuals selected from the Sleep Heart Health study popu-
lation. They found an inverse correlation between AHI and
HDL-cholesterol level. There was a positive relationship be-
tween AHI and diabetes, arterial hypertension and CV dise-
ases (all, CAD, stroke). The correlation between AHI and HF
or stroke was even stronger than with CAD.
Via all these mechanisms, SDB contributes to increased
mortality [26] and morbidity. The OSA is a risk factor of develo-
ping HF [27] as well as coronary events (myocardial infarction,
coronary artery revascularisation procedures) or death from CV
causes [28]. Untreated OSA may, through sympathetic nervous
system activation, lead to an elevated risk of arrhythmia. It has
been demonstrated that in OSA a peak in sudden death from
cardiac causes is shifted in comparison with the general popula-
tion towards the period of sleeping hours (in the general popula-
tion the risk of sudden death peaks between 6am and noon,
with its nadir from midnight to 6am) [29].
CSA
The CSA may also contribute to cardiac electric instability
[30] and impair the quality of life in HF patients. There is
evidence that treatment of CSA in HF patients may improve
further clinical course. In a trial on 66 patients (29 with and
37 without CSA), the subjects were randomised to either a gro-
up that received CPAP or to a control group. In patients with
CSA, using CPAP resulted in both a significant improvement
in EF at three months and a relative risk reduction of 81% in
the mortality — cardiac transplantation rate [31]. Nocturnal
Cheyne-Stokes respiration is known to be an independent
predictor of cardiac death in patients with EF £ 35% [32]. An
early, small study [33] on 16 male patients with chronic, sta-
ble congestive HF, nine with Cheyne-Stokes respiration and
seven without, showed a significant difference between the
number of deaths in each subgroup over the next few years
of follow-up. In the Cheyne-Stokes respiration subgroup, five
patients died and two received a heart transplant, whereas
only one patient died in the other subgroup. A recently pu-
blished study on 283 patients [34] with congestive HF with
EF < 40%, after implantation of a cardiac resynchronisation
device with cardioverter-defibrillator (CRT-D), confirmed the
high prevalence of SDB (AHI ≥ 5) in this population. It also
proved that both subgroups with OSA and CSA had shorter
times to appropriate CRT-D intervention and higher risks of
ventricular tachyarrhythmia. Importantly, the hazard ratio was
even higher in patients with CSA than with OSA. Generally,
the CSA subgroup tended to have a worse profile of several
parameters used for HF assessment, including serum concen-
tration of NT-proBNP, EF, and VE/VCO2 slope in cardiopul-
monary exercise testing. The CSA has been reported to be
correlated with poor survival in systolic HF, alongside severi-
ty of right ventricular systolic dysfunction and low diastolic
blood pressure [35].
TREATMENT
Therapeutic methods are summarised in Table 3. In some
patients, body position during sleep has a great impact on
the severity of SDB, and avoiding sleeping on one’s back re-
sults in reduction of AHI. Small studies regarding possible
benefits from exercise training in SDB have resulted in con-
tradictory results. An initial study proposed overdrive atrial
pacing as a way of reducing apnoeas, but further research did
not support these findings.
Treatment of obstructive sleep apnoea
Obese patients with OSA are advised to reduce body weight.
Alcohol, smoking and sedative drugs should be avoided.
In some cases, surgical correction of airways (for exam-
ple nasal septum correction, tonsillectomy, uvulopalatopha-
ryngoplasty) may be beneficial. There are also less invasive
strategies of opening airways by using a dental appliance
(oral appliance therapy) such as a mandibular repositioner,
tongue-retaining device or palatal lifting appliance.
The gold standard in OSA treatment is CPAP. The device
maintains positive pressure in the airways, thus preventing
Table 3. Treatment of sleep-disordered breathing
Therapeutic interventions
Obstructive sleep apnoea Central sleep apnoea
GOLD STANDARD: Continuous positive airway pressure IMPORTANT: Optimal treatment of heart failure
Reducing body weight Adaptive pressure support servoventilation
Avoiding alcohol, smoking, sedatives Continuous positive airway pressure
Surgical correction of airways Cardiac resynchronisation therapy
Oxygen supplementation Oxygen supplementation
Adjusting body position during sleep Drugs?
www.kardiologiapolska.pl
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obstruction. There are different protocols for pressure regula-
tion: stable pressure on exhalation and inhalation (CPAP);
two different pressure levels with lower value for exhalation
(BiPAP); low pressure during exhalation and changing pres-
sure during inhalation (ASV, adaptive pressure support servo-
ventilation). The choice of protocol depends on the patient’s
tolerance of the treatment. Nasal mask CPAP may be used
alongside an oral appliance therapy method. Oxygen supple-
mentation may be considered in patients intolerant of me-
chanical devices [36].
Treatment of central sleep apnoea
According to the AHA/ACC statement from 2008 [37], given
the lack of evidence from randomised trials showing a signifi-
cant benefit with respect to hospitalisation or mortality, there
is no consensus as to whether CSA in HF should be treated or
what the best therapy may be.
Optimal treatment of HF may normalise PaCO2, reduce
congestion and thus reduce the tendency to periodic bre-
athing. Carvedilol, like other beta-blockers, reduces sympa-
thetic activation but doesn’t share their negative effect on
melatonin secretion. Theophylline has been proved to redu-
ce the severity of CSA in a five day trial. In patients with HF,
long-term treatment with theophylline is questionable because
of possible adverse effects (for example arrhythmogenic). In
a small study, administration of a single dose of acetazolami-
de before sleep improved CSA and its related daytime symp-
toms [38].
Cardiac resynchronisation therapy (CRT) has been repor-
ted to have a beneficial impact on CSA severity in patients
with HF. The CRT reduced AHI and also improved EF and
exercise capacity, and reduced NYHA functional class.
In patients with CSA undergoing heart transplantation,
CSA may subside, though in such cases OSA may arise.
Nocturnal supplemental oxygen has been shown to have
promising effects in short period studies. Oxygen therapy may
improve maximal exercise capacity. The beneficial effect was
also reflected by decreased overnight urinary noradrenaline
excretion.
If, for patients with OSA, CPAP is considered the optimal
treatment, for patients with CSA, the evidence is not so clear.
In patients with CSA in whom CPAP caused improvement of
SDB, reduction of ventricular arrhythmia, AHI, desaturation,
blood and urinary noradrenaline levels and increased LVEF
was observed. However, the CANPAP study [39], a multi-cen-
tre randomised controlled trial, showed no survival benefit in
a group of 258 patients with HF and CSA. This surprising re-
sult provoked further analysis of the data from this study. There
were concerns that in the subgroup receiving CPAP, mean
AHI remained as high as 19. That might explain unsatisfying
effectiveness of treatment in the whole CPAP subgroup. In post-
hoc analysis, the study population was divided into three gro-
ups: those not receiving CPAP (control), those who were tre-
ated with CPAP and reached AHI < 15 in polysomnography
three months after enrollment (CPAP-CSA–suppressed, 57%),
and finally those whose AHI remained ≥ 15 despite CPAP
(CPAP-CSA–unsuppressed, 43%). CPAP-CSA–suppressed sub-
jects experienced a greater increase in LVEF at three months
and significantly better transplant-free survival than control
subjects, whereas the CPAP-CSA–unsuppressed group did
not [40].
In some patients unresponsive to CPAP, adaptive pres-
sure support servoventilation may be effective. This method
allows different degrees of support in different phases of pe-
riodic breathing and smoothes out periodic breathing. Im-
provement during this treatment was described as more pro-
nounced than that obtained with CPAP or oxygen supple-
mentation.
SLEEP-DISORDERED BREATHING IN
HEART FAILURE WITH PRESERVED LVEF
The data regarding SDB in HF with preserved EF (HFPEF) is
limited in comparison with many studies conducted in con-
gestive HF. There are a few reports suggesting that in HFPEF
the prevalence of sleep-disordered breathing is considerably
high. For example, in a small early study on 20 individuals
with symptomatic HFPEF, Chan et al. [41] found significant
SDB (defined as AHI > 10) in 55% of the patients and its
presence seemed to be related to worse diastolic dysfunc-
tion. Consistent findings were presented by Bitter et al. [42].
In 244 patients, SDB (defined as AHI ≥ 5/h) was present in
69.3% of all subjects; 97 (39.8%) patients had OSA and 72
(29.5%) patients had CSA. Increasing impairment of diastolic
function was related to more severe SDB, particularly CSA.
Patients with SDB had worse exercise capacity.
As to the possible pathophysiology of obstructive apno-
ea in HFPEF patients, Bucca et al. [43] studied 15 individuals
with severe OSA, hypertension, and diastolic HF. The pa-
tients underwent therapy consisting of i.v. furosemide 20 mg
and spironolactone 100 mg, bid for three days. Such diuretic
treatment caused a significant decrease in body weight, blood
pressure and AHI (from 74.89 ± 6.95 to 57.17 ± 5.40/h,
p < 0.001). The authors suggest that this treatment reduced
pharyngeal oedema, which may contribute to SDB.
CONCLUSIONS
Sleep-disordered breathing in HF is very common and is re-
lated to a worsened prognosis. The prevalence of apnoea will
increase with the growing population of HF patients. Further
studies are needed to identify optimal diagnostic and thera-
peutic strategies and address the question of SDB in a large
group of patients with HF with preserved ejection fraction.
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